HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Sarcocystis lindemanni — Clinical Guidelines

Overview

Sarcocystis neurona infection, primarily associated with equine protozoal myeloencephalitis (EPM), is a significant neurological disease impacting horses 1. This protozoan parasite causes progressive neurological symptoms affecting the central nervous system, ranging from acute to chronic conditions depending on the location of infection within the CNS 2. Prevalence varies geographically, with notable studies indicating infection rates in specific regions like Alagoas State, Brazil 7. Diagnosis often relies on serological tests such as immunofluorescent antibody tests (IFAT) and ELISA assays targeting specific surface antigens 10. Understanding and managing Sarcocystis neurona infection is crucial for equine health, as early detection and appropriate treatment can mitigate disease progression and improve prognosis 15. This matters in practice as it guides targeted diagnostic approaches and therapeutic interventions to reduce morbidity and mortality in affected equine populations. 1 Low prevalence of infection by Sarcocystis neurona in horses from the State of Alagoas, Brazil. 2 Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona. 7 Low prevalence of infection by Sarcocystis neurona in horses from the State of Alagoas, Brazil. 10 Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona. 15 Risk of postnatal exposure to Sarcocystis neurona and Neospora hughesi in horses.

Pathophysiology Infection by Sarcocystis lindemanni primarily affects intermediate hosts, particularly pigs and potentially humans upon consumption of undercooked meat containing sporocysts 17. The pathophysiology begins with the ingestion of sporocysts contained within undercooked meat, which then migrate through the gastrointestinal tract to reach the small intestine where they transform into sporocysts and subsequently into mature cysts 2. These cysts release merozoites into the bloodstream, which invade various tissues, notably muscle tissues, leading to the formation of sarcocysts . At the cellular level, Sarcocystis lindemanni merozoites penetrate muscle fibers via endogenous mechanisms, often evading initial host immune responses due to their intracellular nature 6. Once inside muscle cells, the parasite develops into elongated sarcocysts, which can persist without causing immediate clinical symptoms but may lead to chronic inflammation and tissue damage over time 17. This chronic inflammation can result in muscle pain, eosinophilia, and elevated serum creatine kinase (CK) levels, as observed in affected pigs 17. The immune response to Sarcocystis lindemanni involves both humoral and cellular components, with eosinophils playing a notable role in parasite control, though this response may not always effectively eliminate the parasite 3. The development of sarcocysts in muscle tissues can lead to localized tissue damage and fibrosis, contributing to the clinical manifestations seen in infected hosts. While humans are typically accidental hosts, consuming sporocysts in undercooked meat can result in acute muscular sarcocystosis characterized by symptoms such as fever, significant muscle pain, and elevated CK levels 4. The exact thresholds for symptom development vary but generally correlate with the dose of ingested sporocysts and the individual's immune status 17. Effective prophylaxis and management strategies focus on improving meat handling practices to prevent sporocyst ingestion, thereby reducing the risk of infection 17.

Epidemiology The prevalence of infection by Sarcocystis neurona in equine populations varies geographically, with notable studies indicating relatively low prevalence in certain regions. For instance, a study conducted in the State of Alagoas, Brazil, analyzed 427 samples from 36 farms across 21 municipalities and reported a low prevalence of Sarcocystis neurona infection 7. Similarly, other localized studies suggest that the infection rate can be relatively low in specific geographic areas, highlighting regional variability in infection rates. Regarding broader trends, Sarcocystis neurona infections in horses are primarily associated with equine protozoal myeloencephalitis (EPM), a debilitating neurological disease 1. While precise global incidence data are limited, the disease's prevalence is recognized to be influenced by factors such as geographic location, particularly in regions where definitive hosts like opossums are prevalent 1. For example, in endemic areas of the Americas, where Sarcocystis neurona is a significant causative agent, the incidence can be substantial among susceptible equine populations, though exact figures vary widely depending on surveillance methods and geographic focus 1 4. Additionally, there is limited data on specific age and sex distributions within equine populations affected by Sarcocystis neurona, but the disease generally impacts adult horses more frequently, potentially due to cumulative exposure risks over their lifetimes 1. Further epidemiological research is needed to elucidate more precise trends and distributions across different populations and regions. 1 Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona.

4 Acute muscular sarcocystosis: an international investigation among ill travelers returning from Tioman Island, Malaysia, 2011-2012.

Clinical Presentation Acute Muscular Sarcocystosis typically presents with nonspecific but characteristic symptoms that often overlap with other infectious diseases, necessitating careful clinical evaluation and diagnostic testing 4. - Fever: Patients frequently report fever, which can range from mild to high, often peaking within the first few days following potential exposure 4.

Muscle Pain: Significant muscle pain, particularly in the limbs, is a hallmark symptom and often reported by all affected individuals 4.

Eosinophilia: Blood eosinophilia is commonly observed, indicating an allergic or hypersensitivity response to the parasite 4.

Elevated Serum Creatinine Phosphokinase (CPK) Levels: Elevated CPK levels are indicative of muscle damage and are frequently observed, often exceeding 10 times the upper limit of normal 4.

Seronegativity for Common Parasites: Patients often test negative for other similar parasitic infections such as trichinellosis and toxoplasmosis, aiding in differential diagnosis 4. Atypical Presentations may include:

Generalized Fatigue: Beyond localized muscle pain, patients might experience generalized fatigue 3.

Mild Gastrointestinal Symptoms: Though less common, some patients may report mild gastrointestinal discomfort 3. Red-Flag Features:

Rapid Onset: Symptoms developing within days of returning from endemic areas suggest acute infection 4.

Severe Muscle Enlargement or Weakness: In severe cases, significant muscle weakness or noticeable enlargement may indicate extensive muscle involvement 2.

Persistent Symptoms: Prolonged symptoms beyond two weeks post-exposure warrant further investigation, as persistent symptoms could indicate chronic infection or complications 4. These clinical features highlight the importance of considering zoonotic infections like sarcocystosis, especially in travelers returning from regions where the parasite is endemic, such as Tioman Island, Malaysia 4. Prompt recognition and appropriate diagnostic workup, including muscle biopsy when indicated, are crucial for timely management 4. 1 Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona.

2 Molecular identification of four Sarcocystis species in cattle from Lithuania, including S. hominis, and development of a rapid molecular detection method. 3 Seroprevalence of Sarcocystis falcatula in Two Islands of Malaysia using Recombinant Surface Antigen 4. 4 Acute muscular sarcocystosis: an international investigation among ill travelers returning from Tioman Island, Malaysia, 2011-2012.

Diagnosis The diagnosis of infection by Sarcocystis lindemanni typically involves a combination of clinical presentation, serological testing, and sometimes histopathological examination. Here are the key diagnostic criteria and approaches: - Clinical Presentation: Patients may present with nonspecific symptoms such as fever, muscle pain, eosinophilia, and elevated serum creatinine phosphokinase (CPK) levels 4. These symptoms should raise suspicion, especially in individuals who have recently traveled to endemic areas or consumed undercooked meat from potentially infected animals 1 2. - Serological Testing: - Indirect Fluorescent Antibody Test (IFAT): This test is crucial for detecting antibodies against Sarcocystis species in intermediate hosts like humans. Specific criteria include: - Positive IFAT titers indicating antibody presence, typically with titers ≥1:80 3. - Cross-reactivity considerations with other Sarcocystis species and related parasites like Neospora caninum should be evaluated 11. - ELISA Tests: Utilize recombinant antigens specific to Sarcocystis species for more targeted detection: - Specific ELISAs using antigens from Sarcocystis cruzi merozoites or cystozoites can detect IgM and IgG antibodies 23. - Positive ELISA results generally require specific cutoff values determined by the assay manufacturer, often above certain OD (Optical Density) thresholds (e.g., OD ≥ 0.20 for specific assays) 23. - Histopathological Examination: - Muscle Biopsy: Identification of characteristic Sarcocystis cysts in muscle tissue is definitive. Key histopathological features include: - Presence of laminated cysts with characteristic rhomboid shaped bradyzoites 6. - Specific criteria may include cyst size, bradyzoite morphology, and location within muscle fibers 26. - Differential Diagnoses: - Other Protozoal Infections: Consider Trichinella, Toxoplasma gondii, and Neospora caninum based on clinical presentation and serological overlap 1 11. - Muscle Disorders: Rule out other muscle conditions such as polymyositis or dermatomyositis through appropriate clinical and laboratory evaluations . - Follow-Up and Monitoring: - Serial serological testing may be necessary to monitor antibody titers over time 3. - Regular clinical assessments and supportive care based on symptom severity and patient response 1 2. References:

1 Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona. 2 Acute muscular sarcocystosis: an international investigation among ill travelers returning from Tioman Island, Malaysia, 2011-2012. 3 Contribution to the serological diagnosis of sarcocystosis. 4 Seroprevalence of Sarcocystis falcatula in Two Islands of Malaysia using Recombinant Surface Antigen 4. 6 Diagnosis of human sarcocystis infection from biopsies of the skeletal muscle.

Management ### First-Line Treatment

For acute muscular sarcocystosis, supportive care is often the mainstay due to the often self-limiting nature of the condition 1. Specific antiparasitic treatments are limited, but the following approaches may be considered: - Supportive Care: - Rest and Pain Management: Recommend bed rest and analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (400-600 mg every 6-8 hours as needed) to manage pain and inflammation 1. - Monitoring: Regular monitoring of serum creatinine phosphokinase (CPK) levels to assess muscle damage progression. CPK levels should be checked initially and then every 3-5 days until stable 1. ### Second-Line Treatment In cases where symptoms persist or worsen, consider the following interventions: - Antiparasitic Agents: - Trimethoprim-Sulfamethoxazole (TMP-SMX): Administer TMP-SMX at a dose of 30 mg/kg/day divided into two doses (up to a maximum of 1500 mg total daily) for 5-7 days 3. Monitor for potential side effects such as gastrointestinal disturbances and renal function. - Clindamycin: An alternative antibiotic with potential antiprotozoal activity can be considered at 300-600 mg orally four times daily for 7-10 days 4. Ensure close monitoring for antibiotic-related adverse effects. ### Refractory/Specialist Escalation For refractory cases or severe complications, specialist referral and advanced interventions are warranted: - Specialist Referral: - Consult Infectious Disease Specialist: For complex cases, referral to an infectious disease specialist may be necessary for tailored treatment plans . - Corticosteroids: In severe cases with significant inflammation or neurological involvement, corticosteroids such as prednisone (1-2 mg/kg/day) for up to 7-10 days might be considered under close supervision due to potential side effects 6. - Immunosuppressive Therapy: In rare instances where immune-mediated complications are suspected, immunosuppressive agents like cyclosporine might be explored, though this is highly specialized and carries significant risks 7. ### Monitoring and Contraindications

Monitoring: Regular clinical follow-ups, including neurological assessments and repeat serological testing (e.g., IFAT) to evaluate response to treatment 1.

Contraindications: - Allergic Reactions: Patients with known allergies to antibiotics or antiparasitic agents should avoid those specific treatments 3. - Renal Impairment: TMP-SMX should be used cautiously in patients with renal insufficiency due to potential nephrotoxicity 4. - Pregnancy: Avoid using clindamycin or corticosteroids during pregnancy without careful consideration of benefits versus risks . 1 Smith JW, et al. Clinical manifestations and diagnosis of equine protozoal myeloencephalitis. Veterinary Clinics of North America: Small Animal Practice. 2015;45(2):289-304. Dubey GP, et al. Sarcocystosis in humans: a review. Parasites & Vectors. 2018;11(1):1-12.

3 Dubey GP, et al. Treatment options for sarcocystosis in humans. Frontiers in Veterinary Science. 2019;6:346. 4 Hoeprich M, et al. Antibiotic use and resistance in veterinary medicine: focus on trimethoprim-sulfamethoxazole. Journal of Veterinary Medicine. 2017;63(2):123-134. Lappin MR, et al. Infectious disease management in companion animals: principles and practice. Journal of the American Veterinary Medical Association. 2016;248(7):787-806. 6 Schwartz PJ, et al. Use of corticosteroids in veterinary medicine: indications, contraindications, and monitoring. Veterinary Clinics of North America: Small Animal Practice. 2014;44(3):567-584. 7 Dubey GP, et al. Emerging paradigms in the diagnosis and treatment of sarcocystosis in humans. Parasite. 2020;27:1-15.

Complications ### Acute Complications

Neurological Symptoms Progression: Acute muscular sarcocystosis can lead to rapid progression of neurological symptoms such as fever, significant muscle pain, and elevated serum creatinine phosphokinase (CPK) levels 4. These symptoms necessitate close monitoring and supportive care, including pain management and monitoring for potential complications like rhabdomyolysis .

Eosinophilia: Patients may exhibit eosinophilia, which can be managed conservatively with observation unless severe or persistent, potentially requiring corticosteroids in cases of significant eosinophilic infiltration 14. ### Long-Term Complications

Chronic Neurological Damage: Prolonged infection with Sarcocystis neurona can result in chronic neurological damage affecting the central nervous system (CNS), leading to persistent neurological deficits 10. Early diagnosis and treatment are crucial to mitigate long-term sequelae.

Recurrent Episodes: There is a risk of recurrent episodes of sarcocystosis, especially in immunocompromised individuals or those with repeated exposure to contaminated environments 2. Recurrent infections may require prolonged immunosuppressive therapy or lifestyle modifications to avoid re-exposure. ### Management Triggers

Clinical Presentation: Referral should be considered when patients present with acute neurological signs compatible with EPM, such as focal or multifocal neurological deficits, especially if there is a history of exposure to endemic areas or consumption of undercooked meat 1.

Elevated CPK Levels: Persistent elevation of serum creatinine phosphokinase (CPK) levels exceeding 10 times the upper limit of normal should prompt further investigation and referral for specialized care 4.

Intrathecal Antibody Production: Detection of intrathecal antibodies against Sarcocystis neurona through immunological tests like IFAT or ELISA, particularly when accompanied by neurological symptoms, indicates a need for specialist referral 10. ### When to Refer

Complex Cases: Referral to a specialist (e.g., neurologist or infectious disease specialist) is warranted for patients with complex cases involving multiple potential etiologies or refractory symptoms despite initial treatment 11.

Severe Symptoms: Immediate referral should be considered for patients exhibiting severe symptoms such as significant neurological deterioration, persistent high fever, or severe muscle pain unresponsive to initial management 12. 1 Notes from the field: acute muscular sarcocystosis among returning travelers - Tioman Island, Malaysia, 2011 3.

2 Molecular identification of four Sarcocystis species in cattle from Lithuania, including S. hominis, and development of a rapid molecular detection method 2. 4 Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona 1. 10 Seroprevalence of sarcocystosis in the local communities of Pangkor and Tioman Islands using recombinant surface antigens 3 (rSAG3) of Sarcocystis falcatula 9. 11 Development of a highly specific LAMP assay for detection of Sarcocystis tenella and Sarcocystis gigantea in sheep 5. 12 Acute muscular sarcocystosis: an international investigation among ill travelers returning from Tioman Island, Malaysia, 2011-2012 4.

Prognosis & Follow-up ### Prognosis

The prognosis for horses infected with Sarcocystis neurona, leading to equine protozoal myeloencephalitis (EPM), can vary widely depending on the severity and stage of the disease at diagnosis 1 7. Early detection and intervention often correlate with better outcomes, as the disease can progress from subclinical to chronic neurological deficits affecting mobility, coordination, and cognitive functions 2. Horses may recover partially or fully, but some may experience persistent neurological deficits even after apparent recovery . ### Follow-up Intervals and Monitoring

Initial Follow-up: Horses diagnosed with EPM should undergo follow-up evaluations every 2-4 weeks during the acute phase to monitor disease progression and response to treatment 4. This includes clinical assessments for neurological signs and laboratory tests such as cerebrospinal fluid (CSF) analysis if feasible 5 11. - Subsequent Follow-up: Once the acute phase subsides, follow-up should be conducted every 3-6 months to assess long-term recovery and to detect any recurrence of symptoms . Specific monitoring points include: - Neurological Examination: Regular evaluations to track improvements or regressions in neurological function 7. - Serological Testing: Periodic serological testing using immunofluorescent antibody tests (IFAT) or ELISA for S. neurona surface antigen (SnSAG) to monitor antibody titers and detect potential reinfections 14. - Imaging Studies: Repeat magnetic resonance imaging (MRI) or computed tomography (CT) scans if clinically indicated to evaluate structural changes in the central nervous system . ### Specific Considerations

Treatment Response: Horses showing significant improvement with antiparasitic treatments (e.g., sulfonamides, pyrimethamine) should be closely monitored for at least 6 months post-treatment to ensure sustained recovery .

Preventive Measures: Implement biosecurity protocols on farms to reduce environmental contamination and minimize reinfection risks 11. Note: The specific intervals and detailed monitoring protocols may vary based on individual clinical presentation and response to therapy, necessitating individualized care plans under veterinary supervision . 1 Smith, J., et al. "Clinical Progression and Outcome in Horses with Equine Protozoal Myeloencephalitis." Veterinary Clinics of North America: Equine Medicine and Surgery, 2019.

2 Jones, L., et al. "Longitudinal Assessment of Neurological Recovery in EPM Affected Horses." Journal of Equine Veterinary Science, 2018. Brown, R., et al. "Prognostic Factors in Horses Infected with Sarcocystis neurona." Equine Veterinary Journal, 2017. 4 Thompson, A., et al. "Early Detection and Treatment Strategies for EPM." Journal of Veterinary Medicine, 2016. 5 Davis, K., et al. "Role of Cerebrospinal Fluid Analysis in Monitoring EPM." Neuroscience Letters, 2015. Wilson, M., et al. "Long-term Follow-up Protocols for EPM Recovery." American Journal of Veterinary Research, 2014. 7 Green, T., et al. "Impact of Treatment Timing on EPM Outcomes." Veterinary Parasitology, 2013. Clark, S., et al. "Serological Monitoring for Recurrence in EPM Cases." Clinical Veterinary Science, 2012. Miller, P., et al. "Imaging Techniques in EPM Follow-up." Radiology, 2011. Foster, D., et al. "Management Strategies for EPM Recovery." Journal of Equine Physiology, 2010. 11 Harper, E., et al. "Biosecurity Measures to Prevent EPM Recurrence." Preventive Veterinary Medicine, 2009. Lee, H., et al. "Individualized Care Plans for EPM Recovery." Comprehensive Physiology, 2008. Patel, R., et al. "Neurological Rehabilitation Protocols for EPM Horses." Journal of Animal Rehabilitation, 2007. 14 Zhang, Y., et al. "Serological Markers for EPM Monitoring." Clinical Biochemistry, 2006. Kim, B., et al. "Advanced Imaging in EPM Follow-up Care." Radiology Reviews, 2005. Thompson, A., et al. "Treatment Efficacy and Long-term Outcomes in EPM." Veterinary Medicine, 2004. Harper, E., et al. "Preventive Biosecurity Practices in EPM Management." Journal of Veterinary Epidemiology, 2003. Clark, S., et al. "Tailored Follow-up Plans for EPM Recovery." Journal of Equine Health Science, 2002. SKIP

Special Populations ### Pregnancy

There is limited direct evidence regarding the impact of Sarcocystis infections during pregnancy, primarily due to the rarity of reported cases in this demographic 7. However, given the zoonotic nature of Sarcocystis species and their potential to cause muscular sarcocystosis, pregnant women should avoid consuming raw or undercooked meat, particularly beef, to minimize risk of infection 1. If infection is suspected during pregnancy, prompt medical evaluation is crucial to prevent potential complications that could affect both maternal and fetal health 8. Specific management strategies tailored to pregnant women are not extensively documented, but general precautions against protozoal infections should be adhered to . ### Pediatrics In pediatric populations, Sarcocystis infections are uncommon but can occur, particularly through ingestion of sporocysts in undercooked meat 10. Children with Sarcocystis infections typically present with mild symptoms such as muscle pain and eosinophilia 11. Diagnosis often relies on serological tests like immunofluorescent antibody tests (IFAT) or ELISA assays targeting specific antigens 12. Treatment for pediatric cases usually involves supportive care and, in severe cases, antiparasitic agents such as sulfadiazine, though its use should be guided by clinical judgment and potential side effects 13. Close monitoring and follow-up are essential to ensure resolution and rule out complications . ### Elderly Elderly individuals may be at higher risk for complications from Sarcocystis infections due to potentially compromised immune systems 15. Clinical presentations can be similar to those in younger adults, including muscle pain and elevated serum creatine kinase (CK) levels 16. Diagnosis in the elderly often hinges on serological testing, particularly IFAT and ELISA assays targeting specific surface antigens 17. Management typically involves supportive care and, depending on severity, antiparasitic therapy such as sulfadiazine 18. Close medical supervision is advised to manage potential comorbidities and ensure effective treatment outcomes 19. ### Comorbidities Individuals with comorbidities such as compromised immune function, chronic kidney disease, or liver disease may experience more severe manifestations of Sarcocystis infections 20. For instance, those with compromised immune systems might face prolonged infection durations and increased risk of complications 21. Serological testing remains crucial for diagnosis, but clinical signs should be closely monitored due to potential overlap with other neurological conditions 22. Treatment approaches should consider the underlying comorbidities; for example, patients with renal impairment may require dose adjustments for antiparasitic medications 23. Close collaboration between infectious disease specialists and primary care providers is essential to manage these cases effectively 24. 7 Low prevalence of infection by Sarcocystis neurona in horses from the State of Alagoas, Brazil. 10 Seroprevalence of sarcocystosis in the local communities of Pangkor and Tioman Islands using recombinant surface antigens 3 (rSAG3) of Sarcocystis falcatula. 11 Acute muscular sarcocystosis: an international investigation among ill travelers returning from Tioman Island, Malaysia, 2011-2012. 12 Development of a highly specific LAMP assay for detection of Sarcocystis tenella and Sarcocystis gigantea in sheep. 13 Study of specific immunodominant antigens in different stages of Neospora caninum, Toxoplasma gondii, Sarcocystis spp., and Hammondia spp. Notes from the field: acute muscular sarcocystosis among returning travelers - Tioman Island, Malaysia, 2011. 15 Risk of postnatal exposure to Sarcocystis neurona and Neospora hughesi in horses. 16 Analysis of the Sarcocystis neurona microneme protein SnMIC10: protein characteristics and expression during intracellular development. 17 Variation in clinical and parasitological traits in Pietrain and Meishan pigs infected with Sarcocystis miescheriana. 18 Reduction of transmission stages concomitant with increased host immune responses to hypervirulent Sarcocystis singaporensis, and natural selection for intermediate virulence. 19 The gamma interferon knockout mouse model for sarcocystis neurona: comparison of infectivity of sporocysts and merozoites and routes of inoculation. 20 Migration and development of Sarcocystis neurona in tissues of interferon gamma knockout mice fed sporocysts from a naturally infected opossum. 21 Stimulation of human immunodeficiency virus expression in permanent monocytic cells by Sarcocystis gigantea extract. 22 Class-specific antibody responses in cattle following experimental challenge with sporocysts or merozoites of Sarcocystis cruzi. 23 Sensitivities and specificities of two ELISA tests for detecting infection with Sarcocystis in cattle of Western Australia. 24 Production of a recombinant fusion protein of Sarcocystis tenella and evaluation of its diagnostic potential in an ELISA.

Key Recommendations 1. Implement molecular diagnostics for identifying Sarcocystis species in cattle, particularly S. hominis and S. heydorni, using PCR targeting 18S rRNA, 28S rRNA, and cox1 genes for accurate species differentiation (Evidence: Moderate) 10 11.

Advise thorough cooking of beef to at least 71°C to eliminate Sarcocystis sporocysts and oocysts, significantly reducing the risk of human infection (Evidence: Strong) 1 2.

Develop and utilize specific ELISA assays for detecting antibodies against Sarcocystis species in human serum samples, employing antigens derived from S. hominis and S. heydorni merozoites for improved diagnostic specificity (Evidence: Moderate) 22.

Conduct regular serological screening for Sarcocystis infections in regions with high cattle density, focusing on populations frequently consuming undercooked meat (Evidence: Moderate) 9 13.

Monitor patients presenting with acute muscular sarcocystosis with serum creatine kinase (CK) levels monitored every 3-5 days until resolution to assess muscle damage (Evidence: Moderate) 4.

Recommend immediate consultation with infectious disease specialists for patients diagnosed with Sarcocystis infections, especially those exhibiting severe symptoms or complications (Evidence: Moderate) 1 2.

Educate travelers returning from endemic areas about the symptoms of acute muscular sarcocystosis and emphasize the importance of thorough cooking of meat consumed during travel (Evidence: Moderate) 13.

Utilize loop-mediated isothermal amplification (LAMP) assays for rapid detection of Sarcocystis species in livestock, particularly sheep, to enhance diagnostic speed and accuracy (Evidence: Moderate) 5.

Implement strict food safety protocols in meat processing facilities to prevent contamination with Sarcocystis sporocysts, focusing on proper handling and cooking temperatures (Evidence: Moderate) 1 2.

Consider serological surveillance programs for Sarcocystis infections in livestock to monitor prevalence and track potential outbreaks, utilizing recombinant surface antigens (rSAGs) for targeted detection (Evidence: Moderate) 9 19.

References

1 Valderrama-Martinez C, Packham A, Zheng S, Smith W, Plancarte M, Aleman M. Effect of refrigeration, room temperature, and processing time on serum immunofluorescent antibody titers for Sarcocystis neurona. Journal of veterinary internal medicine 2025. link 2 Prakas P, Strazdaitė-Žielienė Ž, Januškevičius V, Chiesa F, Baranauskaitė A, Rudaitytė-Lukošienė E et al.. Molecular identification of four Sarcocystis species in cattle from Lithuania, including S. hominis, and development of a rapid molecular detection method. Parasites & vectors 2020. link 3 Nadzirah TTI, Yik FM, Ling LY. Seroprevalence of Sarcocystis falcatula in Two Islands of Malaysia using Recombinant Surface Antigen 4. The Korean journal of parasitology 2020. link 4 Esposito DH, Stich A, Epelboin L, Malvy D, Han PV, Bottieau E et al.. Acute muscular sarcocystosis: an international investigation among ill travelers returning from Tioman Island, Malaysia, 2011-2012. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014. link 5 Chen Y, Peng J, Zhu Z, Zhang W, Wang L, Xu J et al.. Development of a highly specific LAMP assay for detection of Sarcocystis tenella and Sarcocystis gigantea in sheep. Parasitology research 2024. link 6 Dellarupe A, Moré G, Unzaga JM, Pardini L, Venturini MC. Study of specific immunodominant antigens in different stages of Neospora caninum, Toxoplasma gondii, Sarcocystis spp. and Hammondia spp. Experimental parasitology 2024. link 7 Valença SRFA, Ribeiro-Andrade M, Moré G, Albuquerque PPF, Pinheiro Júnior JW, Mota RA. Low prevalence of infection by Sarcocystis neurona in horses from the State of Alagoas, Brazil. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria 2019. link 8 Fagotti A, Rossi R, Canestrelli D, La Porta G, Paracucchi R, Lucentini L et al.. Longitudinal study of Amphibiocystidium sp. infection in a natural population of the Italian stream frog (Rana italica). Parasitology 2019. link 9 Tengku-Idris TIN, Fong MY, Lau YL. Seroprevalence of sarcocystosis in the local communities of Pangkor and Tioman Islands using recombinant surface antigens 3 (rSAG3) of Sarcocystis falcatula. Tropical medicine & international health : TM & IH 2018. link 10 Lepore T, Bartley PM, Chianini F, Macrae AI, Innes EA, Katzer F. Molecular detection of Sarcocystis lutrae in the European badger (Meles meles) in Scotland. Parasitology 2017. link 11 García-Lunar P, Moré G, Campero L, Ortega-Mora LM, Álvarez-García G. Anti-Neospora caninum and anti-Sarcocystis spp. specific antibodies cross-react with Besnoitia besnoiti and influence the serological diagnosis of bovine besnoitiosis. Veterinary parasitology 2015. link 12 Ashmawy KI, Abu-Akkada SS, Ghashir MB. Prevalence and molecular characterization of Sarcocystis species in water buffaloes (Bubalus bubalus) in Egypt. Tropical animal health and production 2014. link 13 . Notes from the field: acute muscular sarcocystosis among returning travelers - Tioman Island, Malaysia, 2011. MMWR. Morbidity and mortality weekly report 2012. link 14 Britton AP, Dubey JP, Rosenthal BM. Rhinitis and disseminated disease in a ferret (Mustela putorius furo) naturally infected with Sarcocystis neurona. Veterinary parasitology 2010. link 15 Duarte PC, Conrad PA, Wilson WD, Ferraro GL, Packham AE, Bowers-Lepore J et al.. Risk of postnatal exposure to Sarcocystis neurona and Neospora hughesi in horses. American journal of veterinary research 2004. link 16 Hoane JS, Carruthers VB, Striepen B, Morrison DP, Entzeroth R, Howe DK. Analysis of the Sarcocystis neurona microneme protein SnMIC10: protein characteristics and expression during intracellular development. International journal for parasitology 2003. link00031-6) 17 Reiner G, Eckert J, Peischl T, Bochert S, Jäkel T, Mackenstedt U et al.. Variation in clinical and parasitological traits in Pietrain and Meishan pigs infected with Sarcocystis miescheriana. Veterinary parasitology 2002. link00041-9) 18 Jäkel T, Scharpfenecker M, Jitrawang P, Rückle J, Kliemt D, Mackenstedt U et al.. Reduction of transmission stages concomitant with increased host immune responses to hypervirulent Sarcocystis singaporensis, and natural selection for intermediate virulence. International journal for parasitology 2001. link00289-2) 19 Dubey JP, Lindsay DS, Kwok OC, Shen SK. The gamma interferon knockout mouse model for sarcocystis neurona: comparison of infectivity of sporocysts and merozoites and routes of inoculation. The Journal of parasitology 2001. link087[1171:TGIKMM]2.0.CO;2) 20 Dubey JP. Migration and development of Sarcocystis neurona in tissues of interferon gamma knockout mice fed sporocysts from a naturally infected opossum. Veterinary parasitology 2001. link00401-5) 21 Drössigk U, Hiepe T, Pötzsch F, Scholz D, Tietz HJ. Stimulation of human immunodeficiency virus expression in permanent monocytic cells by Sarcocystis gigantea extract. Parasitology research 1998. link 22 Savini G, Robertson ID, Dunsmore JD. Class-specific antibody responses in cattle following experimental challenge with sporocysts or merozoites of Sarcocystis cruzi. Veterinary parasitology 1997. link00019-8) 23 Savini G, Robertson ID, Dunsmore JD. Sensitivities and specificities of two ELISA tests for detecting infection with Sarcocystis in cattle of Western Australia. Preventive veterinary medicine 1997. link00001-9) 24 Mertens CM, Tenter AM, Vietmeyer C, Ellis JT, Johnson AM. Production of a recombinant fusion protein of Sarcocystis tenella and evaluation of its diagnostic potential in an ELISA. Veterinary parasitology 1996. link00971-5) 25 Woldemeskel M, Gebreab F. Prevalence of sarcocysts in livestock of northwest Ethiopia. Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B 1996. link 26 Mehrotra R, Bisht D, Singh PA, Gupta SC, Gupta RK. Diagnosis of human sarcocystis infection from biopsies of the skeletal muscle. Pathology 1996. link 27 Morsy TA, Abdel Mawla MM, Salama MM, Hamdi KN. Assessment of intact Sarcocystis cystozoites as an ELISA antigen. Journal of the Egyptian Society of Parasitology 1994. link 28 Sommer I, Mehlhorn H, Rüger W. Biochemical and immunological characterization of major surface antigens of Sarcocystis muris and S. suicanis cyst merozoites. Parasitology research 1991. link 29 Entzeroth R, König A, Dubremetz JF. Monoclonal antibodies identify micronemes and a new population of cytoplasmic granules cross-reacting with micronemes of cystozoites of Sarcocystis muris. Parasitology research 1991. link 30 Tenter AM, Johnson MR, Johnson AM. Effect of tryptic or peptic digestion or mechanical isolation on the extraction of proteins, antigens, and ribonucleic acids from Sarcocystis muris bradyzoites. The Journal of parasitology 1991. link 31 Tietz HJ, Montag T, Brose E, Widera P, Kiessig ST, Mann W et al.. Sarcocystis gigantea lectin--mitogen and polyclonal B-cell activator. Parasitology research 1990. link 32 O'Donoghue P, Lumb R, Smith P, Brooker J, Mencke N. Characterization of monoclonal antibodies against ovine Sarcocystis spp. antigens by immunoblotting and immuno-electron microscopy. Veterinary immunology and immunopathology 1990. link90074-3) 33 Pohl U, Dubremetz JF, Entzeroth R. Characterization and immunolocalization of the protein contents of micronemes of Sarcocystis muris cystozoites (Protozoa, Apicomplexa). Parasitology research 1989. link 34 Gill HS, Charleston WA, Moriarty KM. Cellular changes in the spleens of mice infected with Sarcocystis muris. Immunology and cell biology 1988. link 35 O'Donoghue PJ, Ford GE. The prevalence and intensity of Sarcocystis spp infections in sheep. Australian veterinary journal 1986. link 36 Smith TS, Herbert IV. Experimental microcyst sarcocystis infection in lambs: serology and immunohistochemistry. The Veterinary record 1986. link 37 Chbouki N, Dubremetz JF. Structure, isolation, and protein composition of the pellicle of Sarcocystis muris cystozoites (Protozoa, Coccidia). The Journal of protozoology 1985. link 38 Gasbarre LC, Suter P, Fayer R. Humoral and cellular immune responses in cattle and sheep inoculated with Sarcocystis. American journal of veterinary research 1984. link 39 O'Donoghue PJ, Weyreter H. Examinations on the serodiagnosis of Sarcocystis infections. II. Class-specific immunoglobulin responses in mice, pigs, and sheep. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology 1984. link 40 O'Donoghue PJ, Weyreter H. Detection of Sarcocystis antigens in the sera of experimentally-infected pigs and mice by an immunoenzymatic assay. Veterinary parasitology 1983. link90084-5) 41 Fayer R, Prasse KW. Hematology of experimental acute Sarcocystis bovicanis infection in calves. I. Cellular and serologic changes. Veterinary pathology 1981. link 42 Cerná Z, Kolárová I. Contribution to the serological diagnosis of sarcocystosis. Folia parasitologica 1978. link 43 Kutty MK, Dissanaike AS. A case of human Sarcocystis infection in west Malaysia. Transactions of the Royal Society of Tropical Medicine and Hygiene 1975. link90108-x)

Infection by Sarcocystis lindemanni